As of December 14, 2022, the COVID-NMA revised its protocol and stopped including pharmacological interventions trials. List of studies included but not extracted here
| Arends EJ,J. Am. Soc. Nephrol, 2022 |
Antiviral Effects of Voclosporin on SARS-CoV-2 in Immunocompromised Kidney Patients |
| Cafardi J, JAMA Netw Open, 2022 |
Efficacy and Safety of Pacritinib vs Placebo for Patients With Severe COVID-19: A Phase 2 Randomized Clinical Trial. |
| Corral-Gudino L, Eur J Clin Invest, 2022 |
Effect of intravenous pulses of methylprednisolone 250 mg versus dexamethasone 6 mg in hospitalized adults with severe COVID-19 pneumonia: an open-label randomized trial |
| Denkinger C M, medrxiv, 2022 |
Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 via increased neutralizing antibody activity. A randomized clinical trial |
| Hepprich M, EClinicalMedicine, 2022 |
Canakinumab in patients with COVID-19 and type 2 diabetes - A multicentre, randomised, double-blind, placebo-controlled trial |
| Ilaria Mastrorosa I, SSRN, 2022 |
Sarilumab Plus Standard of Care Versus Standard of Care for the Treatment of Severe COVID-19: A Phase 3, Randomized, Open-Labeled, Multi-Center Study (ESCAPE Study) |
| Jalili E, Tanaffos, 2022 (PRESECO) |
Effect of Convalescent Plasma Therapy on Clinical Improvement of COVID-19 Patients: a Randomized Clinical Trial |
| Ko ER, medrxiv, 2022 |
Abatacept for Treatment of Adults Hospitalized with Moderate or Severe Covid-19 |
| Mastrorosa I, Top. antivir. Med, 2022 |
SARILUMAB PLUS STANDARD of CARE (SOC) VERSUS SOC for SEVERE COVID-19 (ESCAPE STUDY) |
| McMahon JH, EClinicalMedicine, 2022 |
Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial |
| Muller-Tidow C, Hemasphere, 2022 |
A RANDOMIZED CONTROLLED CLINICAL TRIAL DEMONSTRATES THAT PLASMA FROM CONVALESCENT AND VACCINATED DONORS IMPROVES OUTCOME OF COVID-19 IN PATIENTS WITH HEMATOLOGICAL DISEASE, CANCER OR IMMUNOSUPPRESSION |
| NCT04448756 |
M5049 Study in Participants With Coronavirus Disease 2019 (COVID-19) Pneumonia |
| NCT04472494 |
Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise |
| NCT04480424 |
Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19) |
| O'Halloran J, medrxiv, 2022 |
Infliximab for Treatment of Adults Hospitalized with Moderate or Severe Covid-19 |
| Rein L, Crit Care Med, 2022 |
Randomized Phase 3 Trial of Ruxolitinib for COVID-19-Associated Acute Respiratory Distress Syndrome |
| Salton F, Eur Respir J, 2022 |
Prolonged higher dose methylprednisolone vs. conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS). |
| Terada J, Drug Discov Ther, 2022 |
Impact of inhaled ciclesonide on asymptomatic or mild COVID-19: a randomized trial |
| Thorlacius-Ussing L, Sci Rep, 2022 |
A randomized placebo-controlled trial of convalescent plasma for adults hospitalized with COVID-19 pneumonia. |
| Ullah S, Medicina (Kaunas), 2022 |
Assessment of Tocilizumab (Humanized Monoclonal Antibody) for Therapeutic Efficacy and Clinical Safety in Patients with Coronavirus Disease (COVID-19) |
| Villanueva C, medrxiv, 2022 |
Efficacy and safety of convalescent plasma versus standard care in hospitalized patients with COVID-19 from the Peruvian Social Security Health System: open-label, randomized, controlled clinical trial |
| Wu H, PloS one, 2022 |
Low-dose versus high-dose dexamethasone for hospitalized patients with COVID-19 pneumonia: a randomized clinical trial |